Plasma D-dimer (fibrin degradation by-product) is increased in breast cancer and correlates with tumour stage, poor prognosis molecular phenotypes oestrogen receptor (ER) negative, human epidermal growth factor receptor 2 (HER-2) positive [35, 36], circulating tumour cells [37, 38] and reduced survival [39]. The gene discussed is ERBB2; the disease is neoplasm.